A MULTICENTER LONGITUDINAL-STUDY COMPARING THE SENSITIVITY OF MONTHLYMRI AFTER STANDARD AND TRIPLE DOSE GADOLINIUM-DTPA FOR MONITORING DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS - IMPLICATIONS FOR PHASE-II CLINICAL-TRIALS

Citation
M. Filippi et al., A MULTICENTER LONGITUDINAL-STUDY COMPARING THE SENSITIVITY OF MONTHLYMRI AFTER STANDARD AND TRIPLE DOSE GADOLINIUM-DTPA FOR MONITORING DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS - IMPLICATIONS FOR PHASE-II CLINICAL-TRIALS, Brain (Print), 121, 1998, pp. 2011-2020
Citations number
49
Categorie Soggetti
Neurosciences,"Clinical Neurology
Journal title
ISSN journal
00068950
Volume
121
Year of publication
1998
Part
10
Pages
2011 - 2020
Database
ISI
SICI code
0006-8950(1998)121:<2011:AMLCTS>2.0.ZU;2-4
Abstract
In this study we assessed the safety, efficacy and cost-effectiveness of the use of triple dose gadolinium-DTPA (Gd) in serial monthly brain MRI of patients with multiple sclerosis, such as could be selected fo r clinical trials. The number of enhancing lesions, the number of new enhancing lesions and the number of active scans were used to evaluate the sensitivity of the contrast-enhanced MRI to disease activity. The dose of Gd, and the effect of introducing a delay between the contras t injection and the scan were both appraised. Every 4 weeks for 3 mont hs, and in two separate sessions, scans were obtained from 40 patients with relapsing-remitting or secondary progressive multiple sclerosis, 5 min (early) and 20 min (delayed) after a standard dose (0.1 mmol/kg ) or triple dose (0.3 mmol/kg) Gd injection, There were 435 enhancing lesions (242 of which were new) on the early standard dose scans, 479 (263 new) on the delayed standard dose, 772 (365 new) on the early tri ple dose and 827 (404 ne cr) on the delayed triple dose. There were 10 9 scans revealing active disease on the early standard dose scans, 112 on the delayed standard dose, 119 on the early triple dose and 120 on the delayed triple dose, Statistical simulations indicated that the s ample sizes needed for both cross-over and parallel-group trials with similar powers are lower if serial monthly triple dose MRI is used. No side-effects were reported and no significant changes in blood test p arameters were found throughout the study. This study shows that the s erial use of triple dose Gd is safe, and that it increases the sensiti vity of serial monthly enhanced MRI in detecting multiple sclerosis ac tivity significantly. Its use should enable preliminary trials of expe rimental therapies for multiple sclerosis to be conducted in small pat ient populations, over a short period of time.